PK-PD – Metabolism

To support preclinical and clinical development programs, ERBC conducts PK-PD and metabolism studies on pharmaceuticals and biotechnology based products.

Conducted in a broad range of administration routes, dosing regimens and animal species, these studies are managed by senior scientists with deep expertise in biology, pharmacology, data analytics and regulatory.

Pharmacokinetic – bioavailability

Species: rat, mouse, rabbit, dog, minipig, marmoset
All administration routes
Analysis of biological samples (plasma, urine, tissues…)

Pharmacodynamic in vivo and in vitro

Deep expertise in human recombinant proteins, notably GSCF, hGH and EPO (in vivo)

In vitro metabolism

Evaluation of metabolism using liver metabolic fractions (S9, microsomes)
Evaluation of metabolism using hepatocytes
Metabolite profiling, identification and quantification
CYP phenotyping assay
CYP induction in human hepatocytes
CYP inhibition in human liver microsomes
Time dependent CYP inhibition in human liver microsomes

Skin Penetration Study

In vitro Skin Absorption (OECD 428) 

Histochemical and immunohistochemical determinations in tissues

Cytochrome p450
Glutathion S-transferase
γ-Glutamyl transpeptidase
Cytochrome oxidase
Adenosine triphosphatase
Glucose-6-phosphate dehydrogenase